Mergers, partnerships and stock splits

And... bloodbath today?                                                                                                                                                                                                                                                                                                                                                                                                                 July 24, 2024 | [Read Online]( It looks like it could be a 🩸bloodbath today with disappointing earnings from TSLA and GOOGL last night. REMEMBER: Friends don’t let friends trade ALONE — join your fellow trading warriors in [Market Masters]( today. Be the best prepared trader on the Street and live to fight another day 🤺. FOCUS LIST🔎 PIRS - Up over 70% in the pre-market after announcing definitive merger agreement with Palvella Therapeutics HOTH - Up over 50% in pre after announcing partnership with LTS Therapy Systems to accelerate novel Alzheimer's treatment ALLR - Up over 20% in pre after encouraging shareholders to Vote FOR the reverse stock split and decrease in authorized shares at AGM scheduled for Jul 26, 2024 SPOTLIGHT💡 New to Options Trading? How does trading ONE Stock, Every Day sound? [Dip your toe in with JW and his crew in Market Navigator!]( $79 TRIAL OFFER ENDS TODAY — TODAY!!!! (share this link with a friend if you’re already a pro!) HOTLIST🔥 PIRS - Up over 70% in the pre-market after announcing definitive merger agreement with Palvella Therapeutics Pieris Pharmaceuticals, Inc. (PIRS) is a biotechnology company that discovers and develops biotechnological applications. In the pre-market this morning, the [company announced]( a definitive merger agreement with Palvella Therapeutics. The proposed merger will create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for serious, rare genetic skin diseases for which there are no FDA-approved therapies. The combined company is expected to have approximately $80.5 million of cash and cash equivalents at closing, including approximately $78.9 million from an oversubscribed private financing with participation from a syndicate of leading healthcare-dedicated investors, which is expected to provide cash runway into the second half of 2027. Anticipated cash and cash equivalents are expected to fund combined company through multiple clinical trial milestones, including pivotal Phase 3 clinical trial results from a single-arm, baseline-controlled clinical trial of QTORIN(™); 3.9% rapamycin anhydrous gel (QTORIN(™); rapamycin) for the treatment of microcystic lymphatic malformations currently being conducted under FDA's Breakthrough Therapy Designation and Fast Track Designation programs QTORIN(™); rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic lymphatic malformations and cutaneous venous malformations, if approved The transactions contemplated by the merger agreement have been unanimously approved by the boards of directors of both companies and are expected to close in the fourth quarter of 2024, subject to approvals by the stockholders of each company. Pre-merger Pieris stockholders are expected to own approximately 18% of the combined company and pre-merger Palvella stockholders are expected to own approximately 82% of the combined company, in each case, prior to the issuance of the shares under the concurrent private financing. Shares of PIRS traded up over 70% in the pre-market in reaction to the news of the merger. The $14.60 area acted as resistance in the pre-market and will be an important level to watch. Above it, targets to the upside are $15 and then the pre-market high at $15.83. Beyond that, $17, $17.60, $18 and $19 come into play. Below $14.60, targets to the downside are $14, $13.38, $13, $12, $10.60, $10 and then a gap fill at $7.98. HOTH - Up over 50% in pre after announcing partnership with LTS Therapy Systems to accelerate novel Alzheimer's treatment Hoth Therapeutics, Inc. (HOTH) is a clinical-stage biopharmaceutical company that focuses on developing therapies for unmet medical needs. In the pre-market this morning, the [company announced]( it had secured a partnership with LTS Therapy Systems to accelerate novel Alzheimer's treatment. The partnership with LTS Therapy Systems LLC (LTS) is to develop and manufacture the HT-ALZ oral film prototype. HT-ALZ is being developed as a novel therapeutic solution for Alzheimer's Disease based on its exciting preclinical results released earlier this year. HT-ALZ's pre-clinical significance lies in its ability to restore cognitive functions and improve quality of life for subjects suffering from Alzheimer's disease. Treatment of pre-clinical subjects showed cognitive benefits that suggest HT-ALZ's mode of action may involve a reduction in brain inflammation, thereby improving cognitive outcomes for Alzheimer's patients. The pre-clinical research shows compelling evidence of HT-ALZ's capacity to improve memory tasks related to the hippocampus and sensorimotor gating, showcasing an important step forward in Alzheimer's disease treatment. HOTH shares traded up over 50% in the pre-market in reaction to the news. The $1.25 area acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $1.50, $1.56, $1.70 and then the pre-market high at $1.94. Beyond that, $2.20, $2.40 and $2.60 come into play. Below $1.25, targets to the downside are $1.20, $1.10 and then a gap fill at $0.9720. Interactive Live Streaming Trade Room Mon-Fri Real time trading, detailed education on options and penny stocks available to you RIGHT NOW — complimentary right now! [Enter the room and trade with us!]( ALLR - Up over 20% in pre after encouraging shareholders to Vote FOR the reverse stock split and decrease in authorized shares at AGM scheduled for Jul 26, 2024 Allarity Therapeutics Inc. (ALLR) is a clinical-stage biopharmaceutical company that engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. In the after-hours yesterday, the [company released]( a PR statement encouraging shareholders to Vote FOR the reverse stock split and decrease in authorized shares at AGM scheduled for Jul 26, 2024. The company stated: the reverse stock split is essential to enabling compliance with this objective. If the reverse stock split is not approved by the Company’s stockholders, the Company’s common stock may be delisted from Nasdaq. Put simply, a Nasdaq delisting could complicate stockholder’s ability to trade the Company’s common stock, impact its stock price and affect stockholder’s ability to buy or sell when desired. Therefore, the Board of Directors emphasizes the importance of this stockholders’ vote, specifically urging for a positive vote FOR the reverse stock split as well as FOR the decrease in authorized shares. The stock traded up over 20% in the pre-market in reaction to the press release. The $0.20 area acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $0.22, $0.24, $0.26, $0.30, $0.33 and then the after-hours high at $0.3589. Below $0.20, targets to the downside are $0.18 and then a gap fill at $0.1665. Below that is all-time lows at $0.1535. MARKET NEWS 📰 P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas! Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 2024 360 WallStreet 62 Calef Hwy. #233 lee, NH 03861, United States of America [Terms of Service](